ପୋମାଲିଡୋମାଇଡ

ପୋମାଲିଡୋମାଇଡ
Clinical data
Trade names	Pomalyst, Imnovid
AHFS/Drugs.com	monograph
MedlinePlus	a613030
data	EU EMA: yes; US DailyMed: Pomalidomide;
Pregnancy; category	AU: X (High risk) ; ;
Routes of; administration	By mouth (capsules)
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	73% (at least)
Protein binding	12–44%
Metabolism	Liver (mostly CYP1A2- and CYP3A4-mediated; some minor contributions by CYP2C19 and CYP2D6)
Elimination half-life	7.5 hours
Excretion	Urine (73%), faeces (15%)
Identifiers
	IUPAC name 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione;
ECHA InfoCard	100.232.884
Chemical and physical data
Formula	C13H11N3O4
Molar mass	୨୭୩.୨୫ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N;
	InChI InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) ; Key:UVSMNLNDYGZFPF-UHFFFAOYSA-N ;
(verify)

ପୋମାଲିଡୋମାଇଡ (ଇଂରାଜୀ ଭାଷାରେ Pomalidomide), ପୋମାଲିଷ୍ଟ ଏବଂ ଇମ୍ନୋଭିଡ ନାମରେ ବିକ୍ରି ହେଉଥିବା ଏକ ଔଷଧ ଯାହା ଏକାଧିକ ମାଇଲୋମା (ଏମଏମ/ MM) ଏବଂ କାପୋସି ସାର୍କୋମା (କେଏସ/ KS) ରୋଗମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ଏମଏମ ପାଇଁ ଏହା ବ୍ୟବହୃତ ହୁଏ ଯେତେବେଳେ ଅନ୍ୟ ଚିକିତ୍ସା ବିଫଳ ହୁଏ ।^[୪] କେଏସ ପାଇଁ ଏହା ବ୍ୟବହୃତ ହୁଏ ଯେତେବେଳେ ଏଚଏଏଆରଟି (<b>highly active antiretroviral therapy</b> (<b>HAART</b>) ପ୍ରଭାବିତ ହୁଏ ନାହିଁ କିମ୍ବା ଯେଉଁମାନେ ଏଚ୍.ଆଇ.ଭି ନକାରାତ୍ମକ ଅଟନ୍ତି ।^[୪] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଥକ୍କା, ସ୍ୱଳ୍ପ ନିଉଟ୍ରୋଫିଲ୍, ସ୍ୱଳ୍ପ ଲାଲ ରକ୍ତ କଣିକା, ବାନ୍ତି, ତରଳ ଝାଡ଼ା, ଅଣନିଶ୍ୱାସ, ଜ୍ୱର ଏବଂ ଥ୍ରୋମ୍ବୋସାଇଟୋପେନିଆ ବା ଅଳ୍ପ ପ୍ଲାଲେଟ୍ ହୋଇପାରେ ।^[୪] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯକୃତ ସମସ୍ୟା, ଟ୍ୟୁମର ଲାଇସିସ ସିଣ୍ଡ୍ରୋମ, ରକ୍ତ ଜମାଟ ବାନ୍ଧିବା ଏବଂ ଆନାଫାଇଲକ୍‌ସିସ ହୋଇପାରେ ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୪] ଏହା ଥାଲିଡୋମାଇଡ ସହିତ ସଦୃଶ ଏବଂ ପ୍ରତିରକ୍ଷା ପ୍ରଣାଳୀକୁ ପରିବର୍ତ୍ତନ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୬] ^[୨]

୨୦୧୩ ମସିହାରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ପୋମାଲିଡୋମାଇଡ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୪] ^[୨] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦ ସପ୍ତାହର ଚିକିତ୍ସା ପାଇଁ ୨୦୨୧ ମସିହାରେ ପ୍ରାୟ ୮,୯୦୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହେଉଥିଲା ।^[୭] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୨୦,୦୦୦ ଡଲାର ଅଟେ ।^[୮]

ଆଧାର

↑ "Pomalidomide (Pomalyst) Use During Pregnancy". Drugs.com. 14 May 2020. Archived from the original on 25 January 2021. Retrieved 21 September 2020.
↑ ^୨.୦ ^୨.୧ ^୨.୨ "Imnovid EPAR". European Medicines Agency (EMA). Archived from the original on 27 October 2020. Retrieved 21 September 2020.
↑ "Imnovid 1 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 16 June 2020. Archived from the original on 26 October 2020. Retrieved 21 September 2020.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ ^୪.୮ "Pomalyst- pomalidomide capsule". DailyMed. 7 December 2017. Archived from the original on 20 October 2020. Retrieved 21 September 2020.
↑ "Imnovid 1 mg Hard Capsules. Summary of Product Characteristics. 5.2 Pharmacokinetic properties" (PDF). Celgene Europe Ltd. p. 22. Archived (PDF) from the original on 27 June 2016. Retrieved 21 August 2016.
↑ "Pomalidomide Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 7 September 2015. Retrieved 28 October 2021.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1004. ISBN 978-0857114105.
↑ "Pomalyst Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 August 2021. Retrieved 28 October 2021.

[Drugs.com_pregnancy-1] "Pomalidomide (Pomalyst) Use During Pregnancy". Drugs.com. 14 May 2020. Archived from the original on 25 January 2021. Retrieved 21 September 2020.

[EPAR2021-2] ୨.୦ ^୨.୧ ^୨.୨ "Imnovid EPAR". European Medicines Agency (EMA). Archived from the original on 27 October 2020. Retrieved 21 September 2020.

[3] "Imnovid 1 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 16 June 2020. Archived from the original on 26 October 2020. Retrieved 21 September 2020.

[PI2021-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ ^୪.୮ "Pomalyst- pomalidomide capsule". DailyMed. 7 December 2017. Archived from the original on 20 October 2020. Retrieved 21 September 2020.

[5] "Imnovid 1 mg Hard Capsules. Summary of Product Characteristics. 5.2 Pharmacokinetic properties" (PDF). Celgene Europe Ltd. p. 22. Archived (PDF) from the original on 27 June 2016. Retrieved 21 August 2016.

[AHFS2021-6] "Pomalidomide Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 7 September 2015. Retrieved 28 October 2021.

[BNF81-7] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1004. ISBN 978-0857114105.

[8] "Pomalyst Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 August 2021. Retrieved 28 October 2021.

[୪]

[୧]

[୩]

[୨]

[୫]

[୬]

[୭]

[୮]